Overview of Ramucirumab’s Journey in India

Dear Dr. Renukaprasad A R, Did you know about ramucirumab's five approved indications? Here they are: 2nd line advanced gastric cancer/ gastroesophageal junction adenocarcinoma 1 st line epidermal growth factor receptor mutated (EGFRm+) metastatic non-small-cell lung cancer (NSCLC) 2 nd line locally advanced or metastatic NSCLC 2 nd line metastatic colorectal cancer 2 nd line advanced or unresectable hepatocellular carcinoma Join us TODAY at 07:30 PM IST to get more insights on ramucirumab for the management of EGFRm+ advanced NSCLC and gastric cancer! We look forward to your active participation in this informative discussion! Highlights: Overview of ramucirumab's journey in India Case presentation: Clinical evidence of ramucirumab as second-line treatment in GC Treatment decisions in EGFRm+ Advanced NSCLC - RELAYing RELAY Join the LIVE Session   One of the World's Largest Online Community of Verified Doctors Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*